Rhona Stein
Garden State Cancer Center
Center for Molecular Medicine and Immunology
Belleville
NJ 07109
USA
Name/email consistency: high
- Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Stein, R., Gupta, P., Chen, X., Cardillo, T.M., Furman, R.R., Chen, S., Chang, C.H., Goldenberg, D.M. Blood (2010)
- Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Stein, R., Smith, M.R., Chen, S., Zalath, M., Goldenberg, D.M. Clin. Cancer Res. (2009)
- CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Stein, R., Mattes, M.J., Cardillo, T.M., Hansen, H.J., Chang, C.H., Burton, J., Govindan, S., Goldenberg, D.M. Clin. Cancer Res. (2007)
- Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Stein, R., Qu, Z., Chen, S., Solis, D., Hansen, H.J., Goldenberg, D.M. Blood (2006)
- CD45 monoclonal antibody mediated cytolysis of human NK and T lymphoma cells. Stein, R. Haematologica (2006)
- Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody. Stein, R., Govindan, S.V., Hayes, M., Griffiths, G.L., Hansen, H.J., Horak, I.D., Goldenberg, D.M. Clin. Cancer Res. (2005)
- Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Stein, R., Qu, Z., Chen, S., Rosario, A., Shi, V., Hayes, M., Horak, I.D., Hansen, H.J., Goldenberg, D.M. Clin. Cancer Res. (2004)
- Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Stein, R., Qu, Z., Cardillo, T.M., Chen, S., Rosario, A., Horak, I.D., Hansen, H.J., Goldenberg, D.M. Blood (2004)
- A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Stein, R., Goldenberg, D.M. Mol. Cancer Ther. (2004)
- Improved iodine radiolabels for monoclonal antibody therapy. Stein, R., Govindan, S.V., Mattes, M.J., Chen, S., Reed, L., Newsome, G., McBride, B.J., Griffiths, G.L., Hansen, H.J., Goldenberg, D.M. Cancer Res. (2003)